Clinical TrialJul 17, 2026, 07:36 AM
Evaxion to present 3-year EVX-01 cancer vaccine data at ESMO
AI Summary
Evaxion A/S announced it will present three-year clinical efficacy data for its personalized cancer vaccine candidate, EVX-01, at the ESMO Congress 2026 in October. The data, stemming from a one-year extension of a Phase 2 trial in advanced melanoma patients, will offer insights into potentially enhanced treatment effects, durability of the immune response, and the vaccine's efficacy as a stand-alone therapy. This builds on previously reported two-year data that demonstrated a 75% Objective Response Rate and impressive durability, with 92% of patients still responding.
Key Highlights
- Evaxion will present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026.
- Data will provide insights into enhanced treatment effects and durability of EVX-01's immune response.
- The three-year data will also show EVX-01's effect as a stand-alone therapy in advanced melanoma patients.
- Previous two-year data showed an Objective Response Rate (ORR) of 75% (12 out of 16 patients).
- 92% of patients were still responding at two years follow-up with no relapses observed.
- 54% of patients experienced a deepened response during treatment.
- EVX-01 induced an immune response in all patients, with 86% of targeted neoantigens generating T-cell responses.
- The global market for melanoma treatments is estimated to grow to $7.4 billion by 2029.
Price Impact
More from EVAX